JP2021501781A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021501781A5 JP2021501781A5 JP2020524777A JP2020524777A JP2021501781A5 JP 2021501781 A5 JP2021501781 A5 JP 2021501781A5 JP 2020524777 A JP2020524777 A JP 2020524777A JP 2020524777 A JP2020524777 A JP 2020524777A JP 2021501781 A5 JP2021501781 A5 JP 2021501781A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- formula
- compound
- halo
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 176
- 125000000217 alkyl group Chemical group 0.000 claims description 134
- 229910052739 hydrogen Inorganic materials 0.000 claims description 90
- 239000001257 hydrogen Substances 0.000 claims description 90
- 208000017169 kidney disease Diseases 0.000 claims description 66
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 58
- 150000002431 hydrogen Chemical class 0.000 claims description 54
- 201000010099 disease Diseases 0.000 claims description 50
- 125000005843 halogen group Chemical group 0.000 claims description 49
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 42
- 150000003839 salts Chemical class 0.000 claims description 39
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 34
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 33
- 239000000203 mixture Substances 0.000 claims description 27
- 229910052757 nitrogen Inorganic materials 0.000 claims description 22
- 125000004429 atom Chemical group 0.000 claims description 20
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 19
- 125000000623 heterocyclic group Chemical group 0.000 claims description 19
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 19
- 125000001153 fluoro group Chemical group F* 0.000 claims description 16
- 125000004474 heteroalkylene group Chemical group 0.000 claims description 16
- 125000004043 oxo group Chemical group O=* 0.000 claims description 16
- 125000003118 aryl group Chemical group 0.000 claims description 14
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 14
- -1 isooxazolyl Chemical group 0.000 claims description 14
- 206010011878 Deafness Diseases 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 12
- 208000016354 hearing loss disease Diseases 0.000 claims description 12
- YAMHXTCMCPHKLN-UHFFFAOYSA-N imidazolidin-2-one Chemical group O=C1NCCN1 YAMHXTCMCPHKLN-UHFFFAOYSA-N 0.000 claims description 11
- 230000000694 effects Effects 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 9
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 9
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 9
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 9
- 125000001072 heteroaryl group Chemical group 0.000 claims description 9
- 125000004076 pyridyl group Chemical group 0.000 claims description 9
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 9
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 8
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 8
- 208000012268 mitochondrial disease Diseases 0.000 claims description 7
- 230000004770 neurodegeneration Effects 0.000 claims description 7
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 7
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical group O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 claims description 6
- 208000023275 Autoimmune disease Diseases 0.000 claims description 6
- 101100072149 Drosophila melanogaster eIF2alpha gene Proteins 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 208000030533 eye disease Diseases 0.000 claims description 6
- COWNFYYYZFRNOY-UHFFFAOYSA-N oxazolidinedione Chemical compound O=C1COC(=O)N1 COWNFYYYZFRNOY-UHFFFAOYSA-N 0.000 claims description 6
- 230000037361 pathway Effects 0.000 claims description 6
- IWELDVXSEVIIGI-UHFFFAOYSA-N piperazin-2-one Chemical group O=C1CNCCN1 IWELDVXSEVIIGI-UHFFFAOYSA-N 0.000 claims description 6
- 125000004193 piperazinyl group Chemical group 0.000 claims description 6
- 208000017520 skin disease Diseases 0.000 claims description 6
- 230000009385 viral infection Effects 0.000 claims description 6
- 102000001554 Hemoglobins Human genes 0.000 claims description 5
- 108010054147 Hemoglobins Proteins 0.000 claims description 5
- 208000036142 Viral infection Diseases 0.000 claims description 5
- 230000010370 hearing loss Effects 0.000 claims description 5
- 231100000888 hearing loss Toxicity 0.000 claims description 5
- 208000027866 inflammatory disease Diseases 0.000 claims description 5
- 208000030159 metabolic disease Diseases 0.000 claims description 5
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 5
- 125000000335 thiazolyl group Chemical group 0.000 claims description 5
- SJHPCNCNNSSLPL-CSKARUKUSA-N (4e)-4-(ethoxymethylidene)-2-phenyl-1,3-oxazol-5-one Chemical group O1C(=O)C(=C/OCC)\N=C1C1=CC=CC=C1 SJHPCNCNNSSLPL-CSKARUKUSA-N 0.000 claims description 4
- ZABMHLDQFJHDSC-UHFFFAOYSA-N 2,3-dihydro-1,3-oxazole Chemical group C1NC=CO1 ZABMHLDQFJHDSC-UHFFFAOYSA-N 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 230000004064 dysfunction Effects 0.000 claims description 4
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical group O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims description 4
- VIESAWGOYVNHLV-UHFFFAOYSA-N 1,3-dihydropyrrol-2-one Chemical group O=C1CC=CN1 VIESAWGOYVNHLV-UHFFFAOYSA-N 0.000 claims description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 3
- MKCBRYIXFFGIKN-UHFFFAOYSA-N bicyclo[1.1.1]pentane Chemical compound C1C2CC1C2 MKCBRYIXFFGIKN-UHFFFAOYSA-N 0.000 claims description 3
- GPRLTFBKWDERLU-UHFFFAOYSA-N bicyclo[2.2.2]octane Chemical compound C1CC2CCC1CC2 GPRLTFBKWDERLU-UHFFFAOYSA-N 0.000 claims description 3
- 208000036546 leukodystrophy Diseases 0.000 claims description 3
- 210000002346 musculoskeletal system Anatomy 0.000 claims description 3
- CDCHBOQVXIGZHA-UHFFFAOYSA-N 1,2-dihydropyrrol-5-one Chemical group O=C1NCC=C1 CDCHBOQVXIGZHA-UHFFFAOYSA-N 0.000 claims description 2
- AICIYIDUYNFPRY-UHFFFAOYSA-N 1,3-dihydro-2H-imidazol-2-one Chemical group O=C1NC=CN1 AICIYIDUYNFPRY-UHFFFAOYSA-N 0.000 claims description 2
- IMSODMZESSGVBE-UHFFFAOYSA-N 2-Oxazoline Chemical group C1CN=CO1 IMSODMZESSGVBE-UHFFFAOYSA-N 0.000 claims description 2
- XYVMOLOUBJBNBF-UHFFFAOYSA-N 3h-1,3-oxazol-2-one Chemical group OC1=NC=CO1 XYVMOLOUBJBNBF-UHFFFAOYSA-N 0.000 claims description 2
- 125000005879 dioxolanyl group Chemical group 0.000 claims description 2
- 208000016097 disease of metabolism Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000003176 fibrotic effect Effects 0.000 claims description 2
- 125000002541 furyl group Chemical group 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 239000002955 immunomodulating agent Substances 0.000 claims description 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 6
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000005112 cycloalkylalkoxy group Chemical group 0.000 claims 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 1
- 208000023178 Musculoskeletal disease Diseases 0.000 claims 1
- YJUFCXMAKCLEJZ-UHFFFAOYSA-N [C].N1C(CCC1)=O Chemical group [C].N1C(CCC1)=O YJUFCXMAKCLEJZ-UHFFFAOYSA-N 0.000 claims 1
- SXCHDDWMFBETRA-UHFFFAOYSA-N oxazinan-3-one Chemical group O=C1CCCON1 SXCHDDWMFBETRA-UHFFFAOYSA-N 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 claims 1
- HNJBEVLQSNELDL-YZRHJBSPSA-N pyrrolidin-2-one Chemical group O=C1CC[14CH2]N1 HNJBEVLQSNELDL-YZRHJBSPSA-N 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 description 51
- 0 CCc(cc(cc1)OCC(N[C@](CC2)CC[C@@]2N(CCC(CC(C=CC2*)=CC=C2C(F)(F)F)CC2)C2=O)=O)c1Cl Chemical compound CCc(cc(cc1)OCC(N[C@](CC2)CC[C@@]2N(CCC(CC(C=CC2*)=CC=C2C(F)(F)F)CC2)C2=O)=O)c1Cl 0.000 description 26
- 150000001204 N-oxides Chemical class 0.000 description 19
- 239000012453 solvate Substances 0.000 description 18
- 208000009304 Acute Kidney Injury Diseases 0.000 description 14
- 210000003734 kidney Anatomy 0.000 description 13
- 230000002485 urinary effect Effects 0.000 description 11
- 208000002903 Thalassemia Diseases 0.000 description 10
- 201000004681 Psoriasis Diseases 0.000 description 9
- 206010018364 Glomerulonephritis Diseases 0.000 description 8
- 125000002947 alkylene group Chemical group 0.000 description 8
- 230000001363 autoimmune Effects 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 210000001635 urinary tract Anatomy 0.000 description 8
- 208000001647 Renal Insufficiency Diseases 0.000 description 7
- 206010047115 Vasculitis Diseases 0.000 description 7
- 231100000895 deafness Toxicity 0.000 description 7
- 201000006370 kidney failure Diseases 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- 201000008383 nephritis Diseases 0.000 description 7
- 208000022461 Glomerular disease Diseases 0.000 description 6
- 206010046851 Uveitis Diseases 0.000 description 6
- 208000005615 Interstitial Cystitis Diseases 0.000 description 5
- 208000004880 Polyuria Diseases 0.000 description 5
- 208000005980 beta thalassemia Diseases 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 230000035619 diuresis Effects 0.000 description 5
- 206010025135 lupus erythematosus Diseases 0.000 description 5
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 230000009885 systemic effect Effects 0.000 description 5
- 208000031212 Autoimmune polyendocrinopathy Diseases 0.000 description 4
- 206010010356 Congenital anomaly Diseases 0.000 description 4
- 206010058314 Dysplasia Diseases 0.000 description 4
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 description 4
- 206010016654 Fibrosis Diseases 0.000 description 4
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 4
- 208000010159 IgA glomerulonephritis Diseases 0.000 description 4
- 206010021263 IgA nephropathy Diseases 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- 125000003545 alkoxy group Chemical group 0.000 description 4
- 206010003230 arteritis Diseases 0.000 description 4
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 208000031513 cyst Diseases 0.000 description 4
- 230000004761 fibrosis Effects 0.000 description 4
- 231100000417 nephrotoxicity Toxicity 0.000 description 4
- 201000000306 sarcoidosis Diseases 0.000 description 4
- 208000002320 spinal muscular atrophy Diseases 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 210000005239 tubule Anatomy 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- SHXWCVYOXRDMCX-UHFFFAOYSA-N 3,4-methylenedioxymethamphetamine Chemical compound CNC(C)CC1=CC=C2OCOC2=C1 SHXWCVYOXRDMCX-UHFFFAOYSA-N 0.000 description 3
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 description 3
- 206010003591 Ataxia Diseases 0.000 description 3
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 description 3
- 206010009900 Colitis ulcerative Diseases 0.000 description 3
- 208000011231 Crohn disease Diseases 0.000 description 3
- 208000026292 Cystic Kidney disease Diseases 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- 208000007465 Giant cell arteritis Diseases 0.000 description 3
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 3
- 208000032982 Hemorrhagic Fever with Renal Syndrome Diseases 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 208000014919 IgG4-related retroperitoneal fibrosis Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 208000021642 Muscular disease Diseases 0.000 description 3
- 206010029148 Nephrolithiasis Diseases 0.000 description 3
- 206010029164 Nephrotic syndrome Diseases 0.000 description 3
- 208000033626 Renal failure acute Diseases 0.000 description 3
- 206010038979 Retroperitoneal fibrosis Diseases 0.000 description 3
- 241000519995 Stachys sylvatica Species 0.000 description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 description 3
- 208000024780 Urticaria Diseases 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 208000019425 cirrhosis of liver Diseases 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 230000003890 fistula Effects 0.000 description 3
- 201000005206 focal segmental glomerulosclerosis Diseases 0.000 description 3
- 208000007475 hemolytic anemia Diseases 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 201000011486 lichen planus Diseases 0.000 description 3
- 208000005264 motor neuron disease Diseases 0.000 description 3
- 206010065579 multifocal motor neuropathy Diseases 0.000 description 3
- 230000003387 muscular Effects 0.000 description 3
- 208000009928 nephrosis Diseases 0.000 description 3
- 231100001027 nephrosis Toxicity 0.000 description 3
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 210000004243 sweat Anatomy 0.000 description 3
- 206010043207 temporal arteritis Diseases 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 208000007122 AIDS-Associated Nephropathy Diseases 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 208000010444 Acidosis Diseases 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- 108700037006 Adenine phosphoribosyltransferase deficiency Proteins 0.000 description 2
- 208000008190 Agammaglobulinemia Diseases 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 2
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 241000218236 Cannabis Species 0.000 description 2
- 208000005024 Castleman disease Diseases 0.000 description 2
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 description 2
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 2
- 208000015943 Coeliac disease Diseases 0.000 description 2
- 206010011732 Cyst Diseases 0.000 description 2
- 206010011777 Cystinosis Diseases 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 206010012335 Dependence Diseases 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- 206010015995 Eyelid ptosis Diseases 0.000 description 2
- 206010016717 Fistula Diseases 0.000 description 2
- 206010018372 Glomerulonephritis membranous Diseases 0.000 description 2
- 208000024869 Goodpasture syndrome Diseases 0.000 description 2
- 201000004331 Henoch-Schoenlein purpura Diseases 0.000 description 2
- 206010019617 Henoch-Schonlein purpura Diseases 0.000 description 2
- 208000005176 Hepatitis C Diseases 0.000 description 2
- 208000037147 Hypercalcaemia Diseases 0.000 description 2
- 206010020649 Hyperkeratosis Diseases 0.000 description 2
- 206010020983 Hypogammaglobulinaemia Diseases 0.000 description 2
- 206010021036 Hyponatraemia Diseases 0.000 description 2
- 208000029663 Hypophosphatemia Diseases 0.000 description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
- 208000031814 IgA Vasculitis Diseases 0.000 description 2
- 208000028622 Immune thrombocytopenia Diseases 0.000 description 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 2
- 208000001126 Keratosis Diseases 0.000 description 2
- 208000023768 LCAT deficiency Diseases 0.000 description 2
- 208000003465 Lecithin Cholesterol Acyltransferase Deficiency Diseases 0.000 description 2
- 208000012309 Linear IgA disease Diseases 0.000 description 2
- 208000005777 Lupus Nephritis Diseases 0.000 description 2
- 208000004451 Membranoproliferative Glomerulonephritis Diseases 0.000 description 2
- 206010058799 Mitochondrial encephalomyopathy Diseases 0.000 description 2
- 208000003250 Mixed connective tissue disease Diseases 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 206010028372 Muscular weakness Diseases 0.000 description 2
- 102000006386 Myelin Proteins Human genes 0.000 description 2
- 108010083674 Myelin Proteins Proteins 0.000 description 2
- 201000009623 Myopathy Diseases 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 206010053869 POEMS syndrome Diseases 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 description 2
- 208000031481 Pathologic Constriction Diseases 0.000 description 2
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 208000006311 Pyoderma Diseases 0.000 description 2
- 206010061481 Renal injury Diseases 0.000 description 2
- 102100028255 Renin Human genes 0.000 description 2
- 108090000783 Renin Proteins 0.000 description 2
- 102100036901 SLC2A4 regulator Human genes 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 201000002661 Spondylitis Diseases 0.000 description 2
- 206010042276 Subacute endocarditis Diseases 0.000 description 2
- 206010042742 Sympathetic ophthalmia Diseases 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 2
- 208000034841 Thrombotic Microangiopathies Diseases 0.000 description 2
- 235000011941 Tilia x europaea Nutrition 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 208000025851 Undifferentiated connective tissue disease Diseases 0.000 description 2
- 208000017379 Undifferentiated connective tissue syndrome Diseases 0.000 description 2
- 102000018614 Uromodulin Human genes 0.000 description 2
- 108010027007 Uromodulin Proteins 0.000 description 2
- 208000035868 Vascular inflammations Diseases 0.000 description 2
- 201000011040 acute kidney failure Diseases 0.000 description 2
- 208000012998 acute renal failure Diseases 0.000 description 2
- 206010064930 age-related macular degeneration Diseases 0.000 description 2
- 231100000360 alopecia Toxicity 0.000 description 2
- 201000006288 alpha thalassemia Diseases 0.000 description 2
- 206010002022 amyloidosis Diseases 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 description 2
- 208000020832 chronic kidney disease Diseases 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 201000003278 cryoglobulinemia Diseases 0.000 description 2
- 230000010437 erythropoiesis Effects 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- YUCFVHQCAFKDQG-UHFFFAOYSA-N fluoromethane Chemical compound F[CH] YUCFVHQCAFKDQG-UHFFFAOYSA-N 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 231100000852 glomerular disease Toxicity 0.000 description 2
- 230000002949 hemolytic effect Effects 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 description 2
- 201000006334 interstitial nephritis Diseases 0.000 description 2
- 230000000366 juvenile effect Effects 0.000 description 2
- 201000010901 lateral sclerosis Diseases 0.000 description 2
- 239000004571 lime Substances 0.000 description 2
- 201000003265 lymphadenitis Diseases 0.000 description 2
- 208000002780 macular degeneration Diseases 0.000 description 2
- 201000008350 membranous glomerulonephritis Diseases 0.000 description 2
- 231100000855 membranous nephropathy Toxicity 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 206010063344 microscopic polyangiitis Diseases 0.000 description 2
- 230000002438 mitochondrial effect Effects 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000036473 myasthenia Effects 0.000 description 2
- 210000005012 myelin Anatomy 0.000 description 2
- 230000002956 necrotizing effect Effects 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 208000021090 palsy Diseases 0.000 description 2
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 201000008171 proliferative glomerulonephritis Diseases 0.000 description 2
- 201000001474 proteinuria Diseases 0.000 description 2
- 210000000512 proximal kidney tubule Anatomy 0.000 description 2
- 201000003004 ptosis Diseases 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000008085 renal dysfunction Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 230000037390 scarring Effects 0.000 description 2
- 208000007056 sickle cell anemia Diseases 0.000 description 2
- 230000036262 stenosis Effects 0.000 description 2
- 208000037804 stenosis Diseases 0.000 description 2
- 208000008467 subacute bacterial endocarditis Diseases 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- 230000008359 toxicosis Effects 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- XGWFJBFNAQHLEF-UHFFFAOYSA-N 9-anthroic acid Chemical compound C1=CC=C2C(C(=O)O)=C(C=CC=C3)C3=CC2=C1 XGWFJBFNAQHLEF-UHFFFAOYSA-N 0.000 description 1
- 206010058808 Abdominal compartment syndrome Diseases 0.000 description 1
- 208000019932 Aciduria Diseases 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 208000003918 Acute Kidney Tubular Necrosis Diseases 0.000 description 1
- 206010000748 Acute febrile neutrophilic dermatosis Diseases 0.000 description 1
- 208000026872 Addison Disease Diseases 0.000 description 1
- 206010072609 Adenine phosphoribosyl transferase deficiency Diseases 0.000 description 1
- 208000023434 Alpers-Huttenlocher syndrome Diseases 0.000 description 1
- 208000024985 Alport syndrome Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 241000256844 Apis mellifera Species 0.000 description 1
- 102100030762 Apolipoprotein L1 Human genes 0.000 description 1
- 208000027559 Appetite disease Diseases 0.000 description 1
- 241000726094 Aristolochia Species 0.000 description 1
- 206010060965 Arterial stenosis Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000022211 Arteriovenous Malformations Diseases 0.000 description 1
- 206010003226 Arteriovenous fistula Diseases 0.000 description 1
- 206010003402 Arthropod sting Diseases 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 206010064539 Autoimmune myocarditis Diseases 0.000 description 1
- 206010069002 Autoimmune pancreatitis Diseases 0.000 description 1
- 208000022106 Autoimmune polyendocrinopathy type 2 Diseases 0.000 description 1
- 208000027580 BK-virus nephropathy Diseases 0.000 description 1
- 206010060976 Bacillus infection Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 208000004884 Balkan Nephropathy Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- 235000016068 Berberis vulgaris Nutrition 0.000 description 1
- 241000335053 Beta vulgaris Species 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 206010069632 Bladder dysfunction Diseases 0.000 description 1
- 206010062656 Bladder tamponade Diseases 0.000 description 1
- 241000181212 Bourbon virus Species 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 208000013165 Bowen disease Diseases 0.000 description 1
- 208000019337 Bowen disease of the skin Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000023635 C1q nephropathy Diseases 0.000 description 1
- 208000029574 C3 glomerulopathy Diseases 0.000 description 1
- 201000005965 CAKUT Diseases 0.000 description 1
- 201000002829 CREST Syndrome Diseases 0.000 description 1
- 208000004434 Calcinosis Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010007246 Carboxyhaemoglobinaemia Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000004990 Cardiorenal syndrome Diseases 0.000 description 1
- 208000034103 Castleman-Kojima disease Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 description 1
- 201000000724 Chronic recurrent multifocal osteomyelitis Diseases 0.000 description 1
- 208000010007 Cogan syndrome Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 201000003101 Coloboma Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102100035325 Complement factor H-related protein 5 Human genes 0.000 description 1
- 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 206010011258 Coxsackie myocarditis Diseases 0.000 description 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
- 208000019707 Cryoglobulinemic vasculitis Diseases 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 206010011793 Cystitis haemorrhagic Diseases 0.000 description 1
- 206010011796 Cystitis interstitial Diseases 0.000 description 1
- 241000271305 Daphne laureola Species 0.000 description 1
- 208000002506 Darier Disease Diseases 0.000 description 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 1
- 206010011882 Deafness congenital Diseases 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 208000024940 Dent disease Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 208000013558 Developmental Bone disease Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 208000004986 Diffuse Cerebral Sclerosis of Schilder Diseases 0.000 description 1
- 208000004132 Diffuse mesangial sclerosis Diseases 0.000 description 1
- 201000010374 Down Syndrome Diseases 0.000 description 1
- 208000021866 Dressler syndrome Diseases 0.000 description 1
- 201000004315 EAST syndrome Diseases 0.000 description 1
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 206010014950 Eosinophilia Diseases 0.000 description 1
- 208000035751 Epidemic nephropathy Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 208000004332 Evans syndrome Diseases 0.000 description 1
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 1
- 108010011459 Exenatide Proteins 0.000 description 1
- 208000010368 Extramammary Paget Disease Diseases 0.000 description 1
- 208000024720 Fabry Disease Diseases 0.000 description 1
- 208000011514 Familial renal glucosuria Diseases 0.000 description 1
- 208000026019 Fanconi renotubular syndrome Diseases 0.000 description 1
- 201000006328 Fanconi syndrome Diseases 0.000 description 1
- 208000001308 Fasciculation Diseases 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 208000033431 Finnish type congenital nephrotic syndrome Diseases 0.000 description 1
- 208000010006 Fraser Syndrome Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 208000007522 Fused Kidney Diseases 0.000 description 1
- 208000009432 Galloway-Mowat syndrome Diseases 0.000 description 1
- 206010070538 Gestational hypertension Diseases 0.000 description 1
- 201000006004 Gitelman syndrome Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 206010061431 Glial scar Diseases 0.000 description 1
- 206010018341 Gliosis Diseases 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 208000003807 Graves Disease Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 208000033509 HANAC syndrome Diseases 0.000 description 1
- 206010061192 Haemorrhagic fever Diseases 0.000 description 1
- 206010069395 Haemosiderinuria Diseases 0.000 description 1
- 208000006342 Hajdu-Cheney syndrome Diseases 0.000 description 1
- 208000021727 Hantavirus hemorrhagic fever with renal syndrome Diseases 0.000 description 1
- 208000001204 Hashimoto Disease Diseases 0.000 description 1
- 206010019263 Heart block congenital Diseases 0.000 description 1
- 208000018565 Hemochromatosis Diseases 0.000 description 1
- 208000012925 Hemoglobin H disease Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 108010017480 Hemosiderin Proteins 0.000 description 1
- 102100022123 Hepatocyte nuclear factor 1-beta Human genes 0.000 description 1
- 206010062639 Herpes dermatitis Diseases 0.000 description 1
- 206010067265 Heterotaxia Diseases 0.000 description 1
- 208000002128 Heterotaxy Syndrome Diseases 0.000 description 1
- 206010020112 Hirsutism Diseases 0.000 description 1
- 208000017605 Hodgkin disease nodular sclerosis Diseases 0.000 description 1
- 101100323521 Homo sapiens APOL1 gene Proteins 0.000 description 1
- 101000878134 Homo sapiens Complement factor H-related protein 5 Proteins 0.000 description 1
- 101001045758 Homo sapiens Hepatocyte nuclear factor 1-beta Proteins 0.000 description 1
- 101000984044 Homo sapiens LIM homeobox transcription factor 1-beta Proteins 0.000 description 1
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 description 1
- 101001113490 Homo sapiens Poly(A)-specific ribonuclease PARN Proteins 0.000 description 1
- 241000702617 Human parvovirus B19 Species 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 206010020571 Hyperaldosteronism Diseases 0.000 description 1
- 208000002682 Hyperkalemia Diseases 0.000 description 1
- 206010020669 Hypermagnesaemia Diseases 0.000 description 1
- 208000008852 Hyperoxaluria Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 201000001431 Hyperuricemia Diseases 0.000 description 1
- 208000013038 Hypocalcemia Diseases 0.000 description 1
- 206010021027 Hypomagnesaemia Diseases 0.000 description 1
- 206010021131 Hypouricaemia Diseases 0.000 description 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 1
- 201000003838 Idiopathic interstitial pneumonia Diseases 0.000 description 1
- 208000021330 IgG4-related disease Diseases 0.000 description 1
- 208000024934 IgG4-related mediastinitis Diseases 0.000 description 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 208000031781 Immunoglobulin G4 related sclerosing disease Diseases 0.000 description 1
- 208000004187 Immunoglobulin G4-Related Disease Diseases 0.000 description 1
- 208000020340 Immunotactoid glomerulopathy Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 208000027601 Inner ear disease Diseases 0.000 description 1
- 201000006347 Intellectual Disability Diseases 0.000 description 1
- 206010022530 Intercapillary glomerulosclerosis Diseases 0.000 description 1
- 206010022557 Intermediate uveitis Diseases 0.000 description 1
- 208000029523 Interstitial Lung disease Diseases 0.000 description 1
- 208000002623 Intra-Abdominal Hypertension Diseases 0.000 description 1
- 240000007049 Juglans regia Species 0.000 description 1
- 235000009496 Juglans regia Nutrition 0.000 description 1
- 208000003456 Juvenile Arthritis Diseases 0.000 description 1
- 201000002531 Karyomegalic interstitial nephritis Diseases 0.000 description 1
- 208000011200 Kawasaki disease Diseases 0.000 description 1
- 208000002260 Keloid Diseases 0.000 description 1
- 206010023330 Keloid scar Diseases 0.000 description 1
- 206010023369 Keratosis follicular Diseases 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- 201000003129 Kidney Papillary Necrosis Diseases 0.000 description 1
- 241000110847 Kochia Species 0.000 description 1
- 208000016028 Korean hemorrhagic fever Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 1
- 102100025457 LIM homeobox transcription factor 1-beta Human genes 0.000 description 1
- 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 description 1
- 206010024238 Leptospirosis Diseases 0.000 description 1
- 208000022435 Light chain deposition disease Diseases 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 208000004852 Lung Injury Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 208000009564 MELAS Syndrome Diseases 0.000 description 1
- 208000002569 Machado-Joseph Disease Diseases 0.000 description 1
- 208000002805 Mediastinal fibrosis Diseases 0.000 description 1
- 229920000877 Melamine resin Polymers 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 208000027530 Meniere disease Diseases 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 206010027417 Metabolic acidosis Diseases 0.000 description 1
- 206010027423 Metabolic alkalosis Diseases 0.000 description 1
- 206010027635 Milk-alkali syndrome Diseases 0.000 description 1
- 206010052641 Mitochondrial DNA mutation Diseases 0.000 description 1
- 208000035155 Mitochondrial DNA-associated Leigh syndrome Diseases 0.000 description 1
- 102000006404 Mitochondrial Proteins Human genes 0.000 description 1
- 108010058682 Mitochondrial Proteins Proteins 0.000 description 1
- 201000002169 Mitochondrial myopathy Diseases 0.000 description 1
- 208000026072 Motor neurone disease Diseases 0.000 description 1
- 102100034256 Mucin-1 Human genes 0.000 description 1
- 208000001089 Multiple system atrophy Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000002740 Muscle Rigidity Diseases 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 208000003926 Myelitis Diseases 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 206010028594 Myocardial fibrosis Diseases 0.000 description 1
- 206010054837 Myolipoma Diseases 0.000 description 1
- 208000013233 NARP syndrome Diseases 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 206010029216 Nervousness Diseases 0.000 description 1
- 208000000693 Neurogenic Urinary Bladder Diseases 0.000 description 1
- 206010029279 Neurogenic bladder Diseases 0.000 description 1
- 206010071579 Neuronal neuropathy Diseases 0.000 description 1
- 206010029379 Neutrophilia Diseases 0.000 description 1
- 206010030216 Oesophagitis Diseases 0.000 description 1
- 208000003435 Optic Neuritis Diseases 0.000 description 1
- 206010061323 Optic neuropathy Diseases 0.000 description 1
- 206010058461 Orchitis noninfective Diseases 0.000 description 1
- 241000150452 Orthohantavirus Species 0.000 description 1
- 206010031127 Orthostatic hypotension Diseases 0.000 description 1
- 206010033266 Ovarian Hyperstimulation Syndrome Diseases 0.000 description 1
- 208000025174 PANDAS Diseases 0.000 description 1
- 208000021155 Paediatric autoimmune neuropsychiatric disorders associated with streptococcal infection Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000013234 Pearson syndrome Diseases 0.000 description 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
- 206010034277 Pemphigoid Diseases 0.000 description 1
- 208000008223 Pemphigoid Gestationis Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- QPFYXYFORQJZEC-FOCLMDBBSA-N Phenazopyridine Chemical compound NC1=NC(N)=CC=C1\N=N\C1=CC=CC=C1 QPFYXYFORQJZEC-FOCLMDBBSA-N 0.000 description 1
- 102100023715 Poly(A)-specific ribonuclease PARN Human genes 0.000 description 1
- 206010065159 Polychondritis Diseases 0.000 description 1
- 206010036072 Polyglandular autoimmune syndrome type I Diseases 0.000 description 1
- 206010036073 Polyglandular autoimmune syndrome type II Diseases 0.000 description 1
- 206010064115 Polyglandular autoimmune syndrome type III Diseases 0.000 description 1
- 208000026301 Postoperative Cognitive Complications Diseases 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 208000032319 Primary lateral sclerosis Diseases 0.000 description 1
- 208000024777 Prion disease Diseases 0.000 description 1
- 208000037534 Progressive hemifacial atrophy Diseases 0.000 description 1
- 206010036805 Progressive massive fibrosis Diseases 0.000 description 1
- 206010063181 Propofol infusion syndrome Diseases 0.000 description 1
- 241000241413 Propolis Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010068513 Pulmonary renal syndrome Diseases 0.000 description 1
- 208000003670 Pure Red-Cell Aplasia Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 201000004035 RIDDLE syndrome Diseases 0.000 description 1
- 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 description 1
- 206010065427 Reflux nephropathy Diseases 0.000 description 1
- 201000003604 Renal agenesis Diseases 0.000 description 1
- 206010038366 Renal aneurysm Diseases 0.000 description 1
- 206010064655 Renal aplasia Diseases 0.000 description 1
- 206010049942 Renal artery dissection Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 206010038422 Renal cortical necrosis Diseases 0.000 description 1
- 206010038423 Renal cyst Diseases 0.000 description 1
- 206010068033 Renal fusion anomaly Diseases 0.000 description 1
- 206010038470 Renal infarct Diseases 0.000 description 1
- 208000034955 Renal or urinary tract malformation Diseases 0.000 description 1
- 201000002982 Renal-hepatic-pancreatic dysplasia Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 201000007737 Retinal degeneration Diseases 0.000 description 1
- 206010038934 Retinopathy proliferative Diseases 0.000 description 1
- 206010039020 Rhabdomyolysis Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 208000033368 Right sided atrial isomerism Diseases 0.000 description 1
- 240000000111 Saccharum officinarum Species 0.000 description 1
- 235000007201 Saccharum officinarum Nutrition 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 208000000859 Sickle cell trait Diseases 0.000 description 1
- 206010072610 Skeletal dysplasia Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000010265 Sweet syndrome Diseases 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 208000012169 TAFRO syndrome Diseases 0.000 description 1
- 208000010641 Tooth disease Diseases 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 206010069363 Traumatic lung injury Diseases 0.000 description 1
- 208000026928 Turner syndrome Diseases 0.000 description 1
- 206010046298 Upper motor neurone lesion Diseases 0.000 description 1
- 206010046530 Urinary bladder rupture Diseases 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 208000009788 Urogenital Tuberculosis Diseases 0.000 description 1
- 206010046696 Urogenital fistula Diseases 0.000 description 1
- 208000001445 Uveomeningoencephalitic Syndrome Diseases 0.000 description 1
- 206010058990 Venous occlusion Diseases 0.000 description 1
- 208000033774 Ventricular Remodeling Diseases 0.000 description 1
- 208000025749 Vogt-Koyanagi-Harada disease Diseases 0.000 description 1
- 241000710886 West Nile virus Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000007950 acidosis Effects 0.000 description 1
- 208000026545 acidosis disease Diseases 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 208000007782 acroosteolysis dominant type Diseases 0.000 description 1
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000006229 amino acid addition Effects 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 238000011225 antiretroviral therapy Methods 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- BBFQZRXNYIEMAW-UHFFFAOYSA-N aristolochic acid I Chemical compound C1=C([N+]([O-])=O)C2=C(C(O)=O)C=C3OCOC3=C2C2=C1C(OC)=CC=C2 BBFQZRXNYIEMAW-UHFFFAOYSA-N 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000005744 arteriovenous malformation Effects 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 201000009780 autoimmune polyendocrine syndrome type 2 Diseases 0.000 description 1
- 206010071578 autoimmune retinopathy Diseases 0.000 description 1
- 208000029407 autoimmune urticaria Diseases 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000008959 autophagy deficiency Effects 0.000 description 1
- 208000023351 autosomal dominant familial hematuria-retinal arteriolar tortuosity-contractures syndrome Diseases 0.000 description 1
- 201000003974 autosomal dominant hypocalcemia Diseases 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 206010003882 axonal neuropathy Diseases 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
- JSMRMEYFZHIPJV-UHFFFAOYSA-N bicyclo[2.1.1]hexane Chemical compound C1C2CC1CC2 JSMRMEYFZHIPJV-UHFFFAOYSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 229940084891 byetta Drugs 0.000 description 1
- 230000035563 calcemia Effects 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 208000025616 calcium-alkali syndrome Diseases 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 229930003827 cannabinoid Natural products 0.000 description 1
- 239000003557 cannabinoid Substances 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 230000009787 cardiac fibrosis Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 201000004559 cerebral degeneration Diseases 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 208000007413 cholesterol embolism Diseases 0.000 description 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
- 208000024376 chronic urticaria Diseases 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 208000023124 congenital anomaly of kidney and urinary tract Diseases 0.000 description 1
- 201000004395 congenital heart block Diseases 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 208000017563 cutaneous Paget disease Diseases 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 229960002448 dasatinib Drugs 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 208000006602 delta-Thalassemia Diseases 0.000 description 1
- 208000022401 dense deposit disease Diseases 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 208000006881 esophagitis Diseases 0.000 description 1
- CKSJXOVLXUMMFF-UHFFFAOYSA-N exalamide Chemical compound CCCCCCOC1=CC=CC=C1C(N)=O CKSJXOVLXUMMFF-UHFFFAOYSA-N 0.000 description 1
- 229950010333 exalamide Drugs 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 235000020650 eye health related herbal supplements Nutrition 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 208000002980 facial hemiatrophy Diseases 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 208000030376 fibronectin glomerulopathy Diseases 0.000 description 1
- 231100000854 focal segmental glomerulosclerosis Toxicity 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 208000018090 giant cell myocarditis Diseases 0.000 description 1
- 230000001434 glomerular Effects 0.000 description 1
- 206010061989 glomerulosclerosis Diseases 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- 235000020350 green smoothie Nutrition 0.000 description 1
- 210000002768 hair cell Anatomy 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000008642 heat stress Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 201000002802 hemorrhagic cystitis Diseases 0.000 description 1
- 201000011200 hepatorenal syndrome Diseases 0.000 description 1
- 208000003215 hereditary nephritis Diseases 0.000 description 1
- 208000014188 hereditary optic neuropathy Diseases 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 201000005991 hyperphosphatemia Diseases 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 230000000705 hypocalcaemia Effects 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 208000023692 inborn mitochondrial myopathy Diseases 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 1
- 210000001117 keloid Anatomy 0.000 description 1
- 201000004607 keratosis follicularis Diseases 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 208000005430 kidney cortex necrosis Diseases 0.000 description 1
- 235000019226 kombucha tea Nutrition 0.000 description 1
- 206010023497 kuru Diseases 0.000 description 1
- 208000006443 lactic acidosis Diseases 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 208000002741 leukoplakia Diseases 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 231100000515 lung injury Toxicity 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 201000005857 malignant hypertension Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 208000003531 maternally-inherited Leigh syndrome Diseases 0.000 description 1
- JDSHMPZPIAZGSV-UHFFFAOYSA-N melamine Chemical compound NC1=NC(N)=NC(N)=N1 JDSHMPZPIAZGSV-UHFFFAOYSA-N 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000005135 methemoglobinemia Diseases 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 239000002395 mineralocorticoid Substances 0.000 description 1
- 201000002697 mitochondrial DNA depletion syndrome Diseases 0.000 description 1
- 201000011540 mitochondrial DNA depletion syndrome 4a Diseases 0.000 description 1
- 230000004065 mitochondrial dysfunction Effects 0.000 description 1
- 208000022084 motor paralysis Diseases 0.000 description 1
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 206010028537 myelofibrosis Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 201000003631 narcolepsy Diseases 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 208000008795 neuromyelitis optica Diseases 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 230000000422 nocturnal effect Effects 0.000 description 1
- 208000027134 non-immunoglobulin-mediated membranoproliferative glomerulonephritis Diseases 0.000 description 1
- UMRZSTCPUPJPOJ-KNVOCYPGSA-N norbornane Chemical compound C1C[C@H]2CC[C@@H]1C2 UMRZSTCPUPJPOJ-KNVOCYPGSA-N 0.000 description 1
- 208000030212 nutrition disease Diseases 0.000 description 1
- 208000020911 optic nerve disease Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 206010031129 orthostatic proteinuria Diseases 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 201000002638 post-cardiac arrest syndrome Diseases 0.000 description 1
- 201000011461 pre-eclampsia Diseases 0.000 description 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
- 208000011511 primary membranoproliferative glomerulonephritis Diseases 0.000 description 1
- 208000003476 primary myelofibrosis Diseases 0.000 description 1
- 201000000742 primary sclerosing cholangitis Diseases 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 201000002241 progressive bulbar palsy Diseases 0.000 description 1
- 201000008752 progressive muscular atrophy Diseases 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 229940069949 propolis Drugs 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 201000000196 pseudobulbar palsy Diseases 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 229940070891 pyridium Drugs 0.000 description 1
- 206010038351 renal abscess Diseases 0.000 description 1
- 208000007278 renal glycosuria Diseases 0.000 description 1
- 201000005966 renal hypoplasia Diseases 0.000 description 1
- 208000012263 renal involvement Diseases 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 230000001020 rhythmical effect Effects 0.000 description 1
- 201000001958 right atrial isomerism Diseases 0.000 description 1
- 208000010157 sclerosing cholangitis Diseases 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 210000002955 secretory cell Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 208000018019 sickle cell-hemoglobin c disease syndrome Diseases 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 210000005070 sphincter Anatomy 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000003582 thrombocytopenic effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 208000009174 transverse myelitis Diseases 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000002476 tumorcidal effect Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 208000014001 urinary system disease Diseases 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 201000002327 urinary tract obstruction Diseases 0.000 description 1
- 230000001457 vasomotor Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 208000006542 von Hippel-Lindau disease Diseases 0.000 description 1
- 235000020234 walnut Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762580776P | 2017-11-02 | 2017-11-02 | |
| US62/580,776 | 2017-11-02 | ||
| US201862643071P | 2018-03-14 | 2018-03-14 | |
| US62/643,071 | 2018-03-14 | ||
| PCT/US2018/058963 WO2019090081A1 (en) | 2017-11-02 | 2018-11-02 | Modulators of the integrated stress pathway |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021501781A JP2021501781A (ja) | 2021-01-21 |
| JP2021501781A5 true JP2021501781A5 (https=) | 2021-12-09 |
Family
ID=64650479
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020524777A Pending JP2021501781A (ja) | 2017-11-02 | 2018-11-02 | 統合的ストレス経路の調節剤 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20200347033A1 (https=) |
| EP (1) | EP3704091B1 (https=) |
| JP (1) | JP2021501781A (https=) |
| KR (1) | KR20200096523A (https=) |
| CN (1) | CN112218851A (https=) |
| AU (2) | AU2018360850A1 (https=) |
| BR (1) | BR112020008833A2 (https=) |
| CA (1) | CA3080959A1 (https=) |
| IL (1) | IL274406B2 (https=) |
| MX (1) | MX2020004534A (https=) |
| SG (1) | SG11202004009TA (https=) |
| WO (1) | WO2019090081A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020522553A (ja) * | 2017-06-07 | 2020-07-30 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | Ａｔｆ４経路阻害剤としての化合物 |
| CA3071024A1 (en) | 2017-08-09 | 2019-02-14 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| CN111201245B (zh) | 2017-09-01 | 2024-04-05 | 戴纳立制药公司 | 化合物、组合物和方法 |
| WO2019090088A1 (en) | 2017-11-02 | 2019-05-09 | Calico Life Sciences Llc | Modulators of the integrated stress pathway |
| CN111757739A (zh) | 2017-12-13 | 2020-10-09 | 普拉西斯生物技术有限责任公司 | 整合应激反应路径抑制剂 |
| AU2019282253A1 (en) | 2018-06-05 | 2020-11-26 | Altos Labs, Inc. | Inhibitors of integrated stress response pathway |
| TW202545902A (zh) | 2018-10-11 | 2025-12-01 | 美商嘉來克生命科學有限責任公司 | 整合應激路徑之前藥調節劑 |
| EP3924341A4 (en) | 2019-02-13 | 2022-11-02 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| SG11202108552QA (en) | 2019-02-13 | 2021-09-29 | Denali Therapeutics Inc | Compounds, compositions and methods |
| MX2021012904A (es) | 2019-04-23 | 2022-01-18 | Evotec Int Gmbh | Moduladores de la via de respuesta al estres integrada. |
| EP3959198A1 (en) * | 2019-04-23 | 2022-03-02 | Evotec International GmbH | Modulators of the integrated stress response pathway |
| WO2020252207A1 (en) | 2019-06-12 | 2020-12-17 | Praxis Biotech LLC | Modulators of integrated stress response pathway |
| JP7699595B2 (ja) | 2020-01-28 | 2025-06-27 | エヴォテック・インターナショナル・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 統合的ストレス応答経路の調節因子 |
| CN115190813B (zh) * | 2020-03-11 | 2024-10-15 | 埃沃特克国际有限责任公司 | 整合应激反应途径的调节剂 |
| EP4232153A1 (en) | 2020-10-22 | 2023-08-30 | Evotec International GmbH | Modulators of the integrated stress response pathway |
| EP4232447A1 (en) | 2020-10-22 | 2023-08-30 | Evotec International GmbH | Modulators of the integrated stress response pathway |
| RS66455B1 (sr) | 2020-10-22 | 2025-02-28 | Evotec Int Gmbh | Modulatori puta integrisanog odgovora na stres |
| CN116768877B (zh) * | 2022-05-30 | 2026-03-31 | 中国药科大学 | Isr抑制剂及其制备方法和应用 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
| FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
| US5047406A (en) * | 1989-12-06 | 1991-09-10 | Warner-Lambert Co. | Substituted cyclohexanols as central nervous system agents |
| ATE141502T1 (de) | 1991-01-15 | 1996-09-15 | Alcon Lab Inc | Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen |
| US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
| US5852192A (en) * | 1992-03-11 | 1998-12-22 | Dr. Karl Thomae Gmbh | Cyclic urea derivatives, pharmaceutical compositions containing these compounds and processes for preparing them |
| US5506257A (en) * | 1992-03-26 | 1996-04-09 | University Of British Columbia | Aminocyclohexylamides for antiarrhythmic and anaesthetic uses |
| DE4429079A1 (de) * | 1994-08-17 | 1996-02-22 | Thomae Gmbh Dr K | Cyclische Harnstoffderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| WO2004052862A1 (ja) * | 2002-12-10 | 2004-06-24 | Ono Pharmaceutical Co., Ltd. | 含窒素複素環化合物およびその医薬用途 |
| TW200508224A (en) * | 2003-02-12 | 2005-03-01 | Bristol Myers Squibb Co | Cyclic derivatives as modulators of chemokine receptor activity |
| WO2007008221A2 (en) * | 2004-08-10 | 2007-01-18 | President And Fellows Of Harvard College | DETECTION OF PHOSPHORYLATED eIF2α AS A DIAGNOSTIC TEST FOR EFFICIENCY AND SENSITVITY OF TRANSLATION INITIATION INHIBITORS IN THE TREATMENT OF CANCER AND OTHE R PROLIFERATIVE DISEASES |
| WO2007005214A1 (en) * | 2005-06-29 | 2007-01-11 | Janssen Pharmaceutica, N.V. | Substituted {4(4-phenyl-piperazin-1yl)-cyclohexyl}-urea compounds |
| JP2009190971A (ja) * | 2006-06-06 | 2009-08-27 | Mitsubishi Tanabe Pharma Corp | ２−シアノピロリジン誘導体 |
| EP2205603B1 (en) * | 2007-09-28 | 2014-01-15 | Cyclacel Limited | Pyrimidine derivatives as protein kinase inhibitors |
| CA2794153C (en) * | 2010-03-25 | 2018-01-02 | Glaxosmithkline Llc | Substituted indoline derivatives as perk inhibitors |
| WO2012162025A1 (en) * | 2011-05-20 | 2012-11-29 | President And Fellows Of Harvard College | Methods of selecting cancer patients for treatment with n,n'-diarylurea compounds and n,n'-diarylthiourea compounds |
| TW201348231A (zh) * | 2012-02-29 | 2013-12-01 | Amgen Inc | 雜雙環化合物 |
| US9340549B2 (en) * | 2012-03-05 | 2016-05-17 | Amgen Inc. | Oxazolidinone compounds and derivatives thereof |
| CA2904794C (en) * | 2013-03-15 | 2021-11-23 | Peter Walter | Modulators of the eif2alpha pathway |
| US20160318856A1 (en) * | 2013-09-11 | 2016-11-03 | The Brigham And Women's Hospital, Inc. | Substituted Urea eIF2alpha Kinase Activators |
| TWI695003B (zh) * | 2014-12-23 | 2020-06-01 | 美商基利科學股份有限公司 | 多環胺甲醯基吡啶酮化合物及其醫藥用途 |
| TW201808914A (zh) * | 2016-05-05 | 2018-03-16 | 嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
| ES2968227T3 (es) * | 2016-12-23 | 2024-05-08 | Aquinnah Pharmaceuticals Inc | Compuestos, composiciones y procedimientos de uso |
| WO2018225093A1 (en) * | 2017-06-07 | 2018-12-13 | Glaxosmithkline Intellectual Property Development Limited | Chemical compounds as atf4 pathway inhibitors |
| CA3071825A1 (en) * | 2017-07-31 | 2019-02-07 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| WO2019090090A1 (en) * | 2017-11-02 | 2019-05-09 | Calico Life Sciences Llc | Modulators of the integrated stress pathway |
| IL302440A (en) * | 2020-10-30 | 2023-06-01 | Calico Life Sciences Llc | Combined pressure pathway modulators |
-
2018
- 2018-11-02 JP JP2020524777A patent/JP2021501781A/ja active Pending
- 2018-11-02 US US16/761,394 patent/US20200347033A1/en active Pending
- 2018-11-02 EP EP18815387.8A patent/EP3704091B1/en active Active
- 2018-11-02 KR KR1020207015792A patent/KR20200096523A/ko not_active Ceased
- 2018-11-02 AU AU2018360850A patent/AU2018360850A1/en not_active Abandoned
- 2018-11-02 MX MX2020004534A patent/MX2020004534A/es unknown
- 2018-11-02 CA CA3080959A patent/CA3080959A1/en active Pending
- 2018-11-02 SG SG11202004009TA patent/SG11202004009TA/en unknown
- 2018-11-02 BR BR112020008833-1A patent/BR112020008833A2/pt not_active IP Right Cessation
- 2018-11-02 IL IL274406A patent/IL274406B2/en unknown
- 2018-11-02 WO PCT/US2018/058963 patent/WO2019090081A1/en not_active Ceased
- 2018-11-02 CN CN201880085381.4A patent/CN112218851A/zh active Pending
-
2023
- 2023-03-07 AU AU2023201399A patent/AU2023201399B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021501781A5 (https=) | ||
| JP2021501789A5 (https=) | ||
| JP2021501787A5 (https=) | ||
| JP2021501780A5 (https=) | ||
| JP2021501785A5 (https=) | ||
| JP2021501779A5 (https=) | ||
| JP2021501790A5 (https=) | ||
| JP2021501786A5 (https=) | ||
| JP2021501788A5 (https=) | ||
| RU2020117927A (ru) | Модуляторы интегрированного стресса | |
| RU2020117900A (ru) | Модуляторы интегрированного стресса | |
| AU2019384821B2 (en) | Compositions and methods of modulating short-chain dehydrogenase activity | |
| CN115884810A (zh) | 作为il-17调节剂的咪唑并哒嗪 | |
| CN103214484A (zh) | 作为两面神激酶抑制剂的杂芳基取代的吡咯并[2,3-b]吡啶和吡咯并[2,3-b]嘧啶 | |
| JP7819118B2 (ja) | 短鎖デヒドロゲナーゼ活性を調節する組成物及び方法 | |
| WO2017192813A1 (en) | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | |
| JPWO2020223536A5 (https=) | ||
| CA2575777A1 (en) | Compositions and methods for treatment of colitis using methimazole and/or cyclic thione derivatives | |
| JP2013536194A (ja) | プロリルヒドロキシラーゼインヒビタとしての４−アミノキナゾリン−２−イル−１−ピラゾール−４−カルボン酸化合物 | |
| KR20140094547A (ko) | 1-(5,6-다이클로로-1h-벤조[d]이미다졸-2-일)-1h-피라졸-4-카르복실산의 메글루민 염 제형 | |
| JPWO2021130492A5 (https=) | ||
| JPWO2020077217A5 (https=) | ||
| WO2021002986A2 (en) | Bax inhibitors and uses thereof | |
| TW202015693A (zh) | 治療pi3k 相關病症之給藥方案 | |
| EP3676256B1 (en) | Novel barbituric acid derivatives, their preparation and use thereof as leukocyte transmigration inhibitors and for treating inflammatory diseases, autoimmune diseases and cancer |